(Fighting against New Coronary Pneumonia) Canada officially approves AstraZeneca's antibody combination drug for new crown prevention
China News Agency, Toronto, April 14 (Reporter Yu Ruidong) On April 14, Health Canada approved the long-acting antibody combination drug Evusheld produced by AstraZeneca for the prevention of new coronary pneumonia in immunocompromised people.
Evusheld is a combination of two monoclonal antibodies, Tixagevimab and Cilgavimab, administered by intramuscular injection at different sites.
Health Canada has approved the drug for adults and minors over the age of 12 who weigh at least 40 kilograms who are not infected with the new coronavirus and who have not had recent contact with an infected person.
At the same time, the recipients of the drug should have low immunity, cannot produce an adequate immune response to the new crown vaccination, or belong to those who are not recommended by doctors to be vaccinated against the new crown vaccine.
This medicine is not authorized for the treatment of infected people.
The Ministry of Health of Canada emphasizes that no new crown-related medicines can replace vaccinations.
Vaccines remain the most important tool for epidemic prevention.
Evusheld has previously been approved for marketing in the US, UK and EU.
In addition, the Ministry of Health of Canada has approved a number of other different types of drugs for the treatment of patients with new crown infections, such as Gilead's Veklury, Eli Lilly's Bamlanivimab, Gelan SuSmithKline's Sotrovimab, and Pfizer's oral drug Paxlovid.
(Finish)